SIRT2 and cancer: Recent evidence highlights the role of SIRT2 in serous ovarian carcinoma, where its reduced expression is responsible for cancer progression, promoting cell migration, invasion, lymph node metastasis, and peritoneal dissemination (Du et al., 2017).